Investigational Drug Details
| Drug ID: | D442 |
| Drug Name: | Eflornithine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB06243 |
| DrugBank Description: | Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sanofi Aventis and sold under the brand name Ornidyl in the USA. It is now discontinued. Eflornithine is on the World Health Organization's List of Essential Medicines. |
| PubChem ID: | 3009 |
| CasNo: | 70052-12-9 |
| Repositioning for NAFLD: | Yes |
| SMILES: | NCCCC(N)(C(F)F)C(O)=O |
| Structure: |
|
| InChiKey: | VLCYCQAOQCDTCN-UHFFFAOYSA-N |
| Molecular Weight: | 182.171 |
| DrugBank Targets: | Ornithine decarboxylase |
| DrugBank MoA: | Eflornithine prevents hair growth by inhibiting the anagen phase of hair production. This occurs by eflornithine irreversibly binding (also called suicide inhibition) to ornithine decarboxylase (ODC) and physically preventing the natural substrate ornithine from accessing the active site. |
| DrugBank Pharmacology: | |
| DrugBank Indication: | Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth). |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|